JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: JSKN003|DRUG: Capecitabine tablets|DRUG: Gemcitabine hydrochloride for injection|DRUG: Vinorelbine tartrate injection|DRUG: Paclitaxel for injection (albumin-bound type)|DRUG: Docetaxel injection|DRUG: Eribulin mesylate injection
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd